TLR9 on pDCs was predominantly expressed in the leptomeninges and demyelinating lesions of MS patients and enhanced the secretion of type I IFNs and IFN-α to exacerbate MS (88) (Figure 2). Here, TLR9 is linked to myeloid sarcoma.